Matzim LA — Class III drug recall D-0131-2020
Terminated recall by Teva Pharmaceuticals USA, reported 2019-10-16, distributed nationwide. GMP Deviation: lot not intended for commercial distribution.
| Recall number | D-0131-2020 |
|---|---|
| Product type | Drug |
| Classification | Class III |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Teva Pharmaceuticals USA, Parsippany, NJ, United States |
| Recall initiated | 2019-09-06 |
| Classified | 2019-10-09 |
| Reported by FDA | 2019-10-16 |
| Terminated | 2020-05-19 |
| Distributed | Nationwide (US) |
| Quantity | 5,849 bottles |
| Reason classes | cgmp |
| NDC | 52544-0692-30 |
| Lot numbers | 1344864A |
| Expiration dates | 2020-10 |
Product
Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 240 mg, 30 count bottle, Rx only, Manufactured by: Actabis Laboratories FL, Inc., Fort Lauderdale, FL, Distributed by: Actavis Pharma, Inc., Parsippany, NJ NDC 52544-692-30
Reason for recall
GMP Deviation: lot not intended for commercial distribution.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0131-2020. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.